Travel Vaccine Revenues Increase in 2025

Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025.

On November 14, 2025, the Company stated that its revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness.

Specifically, travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and Tickborne encephalitis vaccines, and supported by the gradual launch of the chikungunya vaccine, Vimkunya®.

Vimkunya is available in the USA, Germany, and France . The global launch has continued throughout the third quarter of 2025, where the vaccine also became available in the United Kingdom and Denmark in September. Vimkunya was also launched in Sweden, Norway, Finland, Italy, and Spain in October.

On February 14, 2025, the U.S. Food and Drug Administration approved Vimkunya for injection for individuals 12 years of age and older who are visiting chikungunya endemic areas such as Cuba.

This travel vaccine is commercailly offered at clinics and travel pharmacies in the USA.